A new deal with Takeda could mean up to $3.6 billion in milestone payments for Poseida TherapeuticsMarket Watch • 10/12/21
Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene TherapiesPRNewsWire • 10/12/21
Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual MeetingPRNewsWire • 10/01/21
Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR SummitPRNewsWire • 08/31/21
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple MyelomaPRNewsWire • 08/30/21
Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021PRNewsWire • 08/12/21
Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021PRNewsWire • 05/11/21
Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual MeetingPRNewsWire • 05/11/21
Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory BoardPRNewsWire • 05/06/21
Poseida Therapeutics to Present at BofA Securities 2021 Virtual Health Care ConferencePRNewsWire • 05/05/21
Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual MeetingPRNewsWire • 04/27/21
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory BoardPRNewsWire • 03/23/21
Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020PRNewsWire • 03/11/21
Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual MeetingPRNewsWire • 12/05/20
Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate CancerPRNewsWire • 11/02/20